Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant Chairman Robert O’Leary

Executive Summary

Valeant Chairman Robert O'Leary died at the age of 62 following a long battle with cancer, company announces Aug. 14. Board elects GlaxoSmithKline Vice Chairman-Pharmaceuticals Robert Ingram, a member of Valeant's board since 2003, to serve as chairman. Ingram has also chaired OSI Pharmaceutical's board since 2003 (1"The Pink Sheet" Jan. 13, 2003, In Brief)...

You may also be interested in...

OSI hires GSK’s Ingram

GlaxoSmithKline Vice Chairman-Pharmaceuticals Robert Ingram joins OSI Pharmaceuticals as chairman of board of directors in a non-executive capacity, effective Jan. 1. "Ingram will assume chairmanship of the Board's executive, nominating and compensation committees," OSI said. OSI CEO Colin Goddard relinquishes chairmanship of board. Ingram retired as GSK chief operating officer and pharmaceutical operations president in December (1"The Pink Sheet" Oct. 21, 2002, p. 27)...

Bayer Confident CureVac COVID Pact Will Be A Success

CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.

EMA Works On Defining Metadata From RWD Sources

As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts